RANI Rani Therapeutics Holdings, Inc.
Listings ·
Rani Therapeutics (Nasdaq: RANI) has until November 9, 2026, to regain bid price compliance. It also reported cash, cash equivalents and marketable securities of $43.4 million and a first quarter net loss of $8.0 million.
Rani Therapeutics filed a resale prospectus on July 11, 2025 covering up to 13,160,172 Class A shares issuable on exercise of a Series D warrant. The company says it will receive no proceeds from the resale itself.
Rani Therapeutics received a Nasdaq notice on June 20, 2025 that its Class A shares had a closing bid price below $1.00 for 30 consecutive business days. Its deadline to regain compliance is December 17, 2025, and the notice gives no closing price.
Rani Therapeutics cut the exercise price of two outstanding warrants from $3.08 and $3.00 to $0.65 so an existing institutional investor would exercise them, for gross proceeds of about $4.3 million before advisory fees. The investor also receives a new Series D warrant for up to 13,160,172 shares.
Rani Therapeutics is a clinical-stage biotherapeutics company developing technology to deliver biologics and drugs orally, as an alternative to injections. Its drug-agnostic platform centers on the RaniPill capsule, which is designed to deliver antibodies, proteins, peptides and oligonucleotides. There are two configurations. The RaniPill GO is designed to deliver up to a 3 mg dose in microtablet form, and the RaniPill HC is a high-capacity version intended for liquid payloads up to 200µL. The company says it has completed three Phase 1 clinical trials with the RaniPill GO. In December 2025 it initiated a Phase 1 trial of RT-114, a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist for obesity. The company does not have any products approved for sale and has not generated product revenue. It is pursuing partnerships to apply its oral delivery technology to third-party biologics and drugs. In October 2025 it entered into a Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd.
| Product or program | What it is | Stage |
|---|---|---|
| RaniPill GO | Oral capsule designed to deliver up to a 3 mg dose in microtablet form | three Phase 1 clinical trials completed |
| RaniPill HC | High-capacity oral capsule for liquid payloads up to 200µL | tested preclinically; in development |
| RT-114 | RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist (PG-102) for obesity | Phase 1 initiated in December 2025 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.6 million | $1.0 million |
| Research and development | $20.2 million | $26.7 million |
| Net income (loss) | -$29.7 million | -$30.0 million |
| Cash from operations | -$18.7 million | -$35.5 million |
| Cash and equivalents | $18.6 million | $3.8 million |
Our latest story on this, dated Jun 26, 2025: "Rani Therapeutics gets Nasdaq notice over $1.00 minimum bid price". The story links the filing or release it is based on. Read the story.
Rani Therapeutics Holdings, Inc. trades under the ticker RANI on NASDAQ.
Rani Therapeutics Holdings, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Rani Therapeutics Holdings, Inc. is 1856725. Its filings are on SEC EDGAR.
Our directory records Rani Therapeutics Holdings, Inc. under United States.
Our directory classifies Rani Therapeutics Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Rani Therapeutics Holdings, Inc. is US7530181004.
aibio.space lists Rani Therapeutics Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as CA.
Rani Therapeutics is a clinical-stage biotherapeutics company developing technology to deliver biologics and drugs orally, as an alternative to injections. Its drug-agnostic platform centers on the RaniPill capsule, which is designed to deliver antibodies, proteins, peptides and oligonucleotides.
RaniPill GO: Oral capsule designed to deliver up to a 3 mg dose in microtablet form Stage: three Phase 1 clinical trials completed.
RaniPill HC: High-capacity oral capsule for liquid payloads up to 200µL Stage: tested preclinically; in development.
$1.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Rani Therapeutics Holdings, Inc. reported a net loss of $29.7 million for the fiscal year ended Dec 31, 2025, and used $18.7 million of cash in operations, per its annual report to the SEC.
$20.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,5.02,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,3.03,5.03,5.07,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio